Quick Takeaways
- Skorpios Trust filed SCHEDULE 13D/A for Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK).
- Disclosed ownership: 13%.
- Date of event: 23 Dec 2024.
Skorpios Trust - 23 Dec 2024 SCHEDULE 13D/A Report for Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK)
- Filing Manager
- Skorpios Trust
- Reporting Manager
- Skorpios Trust
- Symbol
- STOK
- Shares outstanding
- 53,124,469 shares
- Disclosed Ownership
- 6,906,181 shares
- Ownership
- 13%
- Form type
- SCHEDULE 13D/A
- Filing time
- 27 Dec 2024, 17:23:14 UTC
- Date of event
- 23 Dec 2024
- Next filing
- 06 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Skorpios Trust disclosed 13% ownership in Stoke Therapeutics, Inc. Common Stock, $0.0001 par value per share (STOK) on 23 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 27 Dec 2024, 17:23.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Blue Horizon Enterprise Ltd. | 5.6% | 2,967,621 | 0 | 2,967,621 | /s/ Eleni Constantinon Kyriacou | Eleni Constantinon Kyriacou, Director | |
| Ezbon International Limited | 7.4% | 3,938,560 | 0 | 3,938,560 | /s/ Eleni Constantinon Kyriacou | Eleni Constantinon Kyriacou, Director | |
| Montrago Trustees Limited | 13% | 6,906,181 | 0 | 6,906,181 | /s/ Androulla Papadopoulou | Androulla Papadopoulou, Director | |
| Skorpios Trust | 13% | 6,906,181 | 0 | 6,906,181 | /s/ Androulla Papadopoulou | Androulla Papadopoulou, Director | 0001869333 |